Skip to content

Author

A. S. Tullberg

We have 1 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis

Decision modeling to project 10-year survival across recurrence-risk groups to aid in clinical decision-making favors T-DXd for patients with RCB-II or RCB-III disease, and for RCB-I patients, particularly those with ER-positive tumors, the projected survival gain is smaller and sensitive to fatal ILD assumptions.

J. Fan, A. S. Tullberg, A. Kurian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.